Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Pfister

Showing results (11-20 of 156) with videos related to

Pageof 16
Sort By:
American Journal of Therapeutics|September 9, 2005
Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release modelShashank Rohatagi, Sriram Krishnaswami, Marc Pfister, et al.
Pediatric Nephrology (Berlin, Germany)|March 2, 2021
Hemodialysis (HD) dose and ultrafiltration rate are associated with survival in pediatric and adolescent patients on chronic HD-a large observational study with follow-up to young adult ageVerena Gotta, Olivera Marsenic, Andrew Atkinson, et al.
Biologics in Therapy|August 15, 2014
Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary ImmunodeficiencyJagdev Sidhu, Mikhail Rojavin, Marc Pfister, et al.
Therapeutische Umschau. Revue Therapeutique|December 15, 2015
[Understanding and reducing the risk of adverse drug reactions in pediatric patients]Verena Gotta, Johannes van den Anker, Marc Pfister
Expert Opinion on Drug Discovery|July 25, 2012
The current role of model-based drug developmentSatyendra Suryawanshi, Liping Zhang, Marc Pfister, et al.
Journal of Clinical Pharmacology|July 6, 2023
Characterizing Associations of QTc Interval with Nocturnal Glycemic Control in Children with Type 1 DiabetesVerena Gotta, Sara Bachmann, Marc Pfister, et al.
Journal of Clinical Pharmacology|January 11, 2012
Design, conduct, analysis, and interpretation of clinical studies in patients with impaired kidney functionMichael A Tortorici, David Cutler, Lei Zhang, et al.
Journal of Clinical Pharmacology|September 10, 2008
Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemiaGuowei Dai, Marc Pfister, Anne Blackwood-Chirchir, et al.
Clinical and Translational Science|December 10, 2021
Optimizing moxidectin dosing for Strongyloides stercoralis infections: Insights from pharmacometric modelingDaniela Hofmann, Cornelis Smit, Somphou Sayasone, et al.
The Pediatric Infectious Disease Journal|February 11, 2016
Therapeutic Drug Monitoring for Anti-infective Agents in Pediatrics: The Way ForwardNicole Ritz, Julia Bielicki, Marc Pfister, et al.
Pageof 16

Showing results (11-20 of 156) with videos related to

Sort By:
Pageof 16
American Journal of Therapeutics|September 9, 2005
Model-based covariate pharmacokinetic analysis and lack of cortisol suppression by the new inhaled corticosteroid ciclesonide using a novel cortisol release modelShashank Rohatagi, Sriram Krishnaswami, Marc Pfister, et al.
Pediatric Nephrology (Berlin, Germany)|March 2, 2021
Hemodialysis (HD) dose and ultrafiltration rate are associated with survival in pediatric and adolescent patients on chronic HD-a large observational study with follow-up to young adult ageVerena Gotta, Olivera Marsenic, Andrew Atkinson, et al.
Biologics in Therapy|August 15, 2014
Enhancing Patient Flexibility of Subcutaneous Immunoglobulin G Dosing: Pharmacokinetic Outcomes of Various Maintenance and Loading Regimens in the Treatment of Primary ImmunodeficiencyJagdev Sidhu, Mikhail Rojavin, Marc Pfister, et al.
Therapeutische Umschau. Revue Therapeutique|December 15, 2015
[Understanding and reducing the risk of adverse drug reactions in pediatric patients]Verena Gotta, Johannes van den Anker, Marc Pfister
Expert Opinion on Drug Discovery|July 25, 2012
The current role of model-based drug developmentSatyendra Suryawanshi, Liping Zhang, Marc Pfister, et al.
Journal of Clinical Pharmacology|July 6, 2023
Characterizing Associations of QTc Interval with Nocturnal Glycemic Control in Children with Type 1 DiabetesVerena Gotta, Sara Bachmann, Marc Pfister, et al.
Journal of Clinical Pharmacology|January 11, 2012
Design, conduct, analysis, and interpretation of clinical studies in patients with impaired kidney functionMichael A Tortorici, David Cutler, Lei Zhang, et al.
Journal of Clinical Pharmacology|September 10, 2008
Importance of characterizing determinants of variability in exposure: application to dasatinib in subjects with chronic myeloid leukemiaGuowei Dai, Marc Pfister, Anne Blackwood-Chirchir, et al.
Clinical and Translational Science|December 10, 2021
Optimizing moxidectin dosing for Strongyloides stercoralis infections: Insights from pharmacometric modelingDaniela Hofmann, Cornelis Smit, Somphou Sayasone, et al.
The Pediatric Infectious Disease Journal|February 11, 2016
Therapeutic Drug Monitoring for Anti-infective Agents in Pediatrics: The Way ForwardNicole Ritz, Julia Bielicki, Marc Pfister, et al.
Pageof 16